ASCO readouts offer early hints of efficacy for 4-1BB antibodies

LAG3 may be attracting most of the attention at ASCO21, but a trickle of first-in-human readouts for another checkpoint target — 4-1BB — suggests the broader landscape of checkpoint inhibitors could be reaching an inflection point. 

At the American Society of Clinical Oncology virtual meeting, at least three companies will share first-in-human data on mAbs against 4-1BB, one of the checkpoint targets that previously stumbled in the clinic...